Company intelligence / Profile preview

Nutech Mediworld

New Delhi, Delhi, India

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Nutech Mediworld provides human embryonic stem cell (hESC) therapy for various incurable and chronic conditions. The facility claims to have treated over 1,500 patients globally using a proprietary hESC line developed by Dr. Geeta Shroff. Clinical results published in various journals report functional improvements in patients with spinal cord injuries, ALS, and cerebral palsy, though the methodology has been subject to discussion in the broader scientific community.

Therapeutic areas: EndocrinologyNeurologyInfectious DiseasesPsychiatryOphthalmology
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on Nutech Mediworld.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nutech Mediworld.

Explore the full profile